Thompson J A, Rubin E, Fefer A
Department of Medicine, University of Washington School of Medicine, Seattle.
Leukemia. 1987 Apr;1(4):328-30.
Thirty-six patients with progressive hairy cell leukemia were treated with recombinant alpha 2b-interferon injected subcutaneously 2 X 10(6) IU/m2, three times a week. Twenty-seven patients completed 12 months of therapy and were randomized either to receive 6 months of continued interferon or to go off treatment. At the time of randomization, two patients had achieved a complete response, 22 a partial response, and three a minimal response. Three patients have relapsed, one while receiving interferon during the randomization period and two who were off therapy for 6 months. The outpatient regimen of interferon administration was well tolerated, with the principal acute toxicities being fever and an influenza-like syndrome and the major long-term toxicity being mild-moderate fatigue.
36例进行性毛细胞白血病患者接受皮下注射重组α2b干扰素治疗，剂量为2×10(6)IU/m2，每周3次。27例患者完成了12个月的治疗，然后被随机分为两组，一组继续接受6个月的干扰素治疗，另一组停止治疗。随机分组时，2例患者达到完全缓解，22例部分缓解，3例微小缓解。3例患者复发，1例在随机分组期间接受干扰素治疗时复发，2例在停止治疗6个月后复发。门诊干扰素给药方案耐受性良好，主要急性毒性为发热和流感样综合征，主要长期毒性为轻至中度疲劳。
